Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

723181.pdf (2.74 MB)

Document type

Article

Version

Published version

Publication date

2022

Publication license

cc-by (c) Sampietro Pifarre, Anna et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/185413

Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3390/ph15050545

Abstract

Multitarget anti-Alzheimer agents are the focus of very intensive research. Through a comprehensive bibliometric analysis of the publications in the period 1990-2020, we have identified trends and potential gaps that might guide future directions. We found that: (i) the number of publications boomed by 2011 and continued ascending in 2020; (ii) the linked-pharmacophore strategy was preferred over design approaches based on fusing or merging pharmacophores or privileged structures; (iii) a significant number of in vivo studies, mainly using the scopolamine-induced amnesia mouse model, have been performed, especially since 2017; (iv) China, Italy and Spain are the countries with the largest total number of publications on this topic, whereas Portugal, Spain and Italy are the countries in whose scientific communities this topic has generated greatest interest; (v) acetylcholinesterase, beta-amyloid aggregation, oxidative stress, butyrylcholinesterase, and biometal chelation and the binary combinations thereof have been the most commonly pursued, while combinations based on other key targets, such as tau aggregation, glycogen synthase kinase-3beta, NMDA receptors, and more than 70 other targets have been only marginally considered. These results might allow us to spot new design opportunities based on innovative target combinations to expand and diversify the repertoire of multitarget drug candidates and increase the likelihood of finding effective therapies for this devastating disease.

Subject

Malaltia d'Alzheimer, Desenvolupament de medicaments, Química farmacèutica

Subject (English)

Alzheimer's disease, Drug development, Pharmaceutical chemistry

Citation

Collections

Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Citation

SAMPIETRO PIFARRE, Anna, et al. Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis. Pharmaceuticals. 2022. Vol. 15, num. 5, pags. 545. ISSN 1424-8247. [consulted: 17 of August of 2026]. Available at: https://hdl.handle.net/2445/185413

Export metadata

JSON - METS

Share record